Xenon Pharmaceuticals
Xenon Pharmaceuticals Inc is a Canadian biopharmaceutical company engaged in the research, development, and commercialization of ion channel therapies for neurological disorders. The company focuses on developing small molecule therapeutics targeting ion channels to treat epilepsy, depression, and pain indications. Its lead clinical candidate, azetukalner, is an advanced selective Kv7 potassium channel opener in late-stage development for focal onset seizures, primary generalized tonic-clonic seizures, and major depressive disorder. Principal revenue is derived from upfront payments, research milestone achievements, and technology licensing fees paid by global pharmaceutical collaboration partners. Xenon Pharmaceuticals occupies a specialized scientific position in ion channel drug discovery for central nervous system diseases. Headquartered in Vancouver, Canada, the company's common stock is publicly listed and traded on the Nasdaq Global Select Market under the ticker XENE.
15 of the funds FundTelligence covers report a position in Xenon Pharmaceuticals.
- Legal name
- Xenon Pharmaceuticals Inc
- Sector
- Health Care
- Country
- Canada
- Funds holding it
- 15
Funds holding Xenon Pharmaceuticals
- Polar Capital Healthcare Discovery Fund — Polar Capital · 2.7 % (largest positions only, October 2026)
- DNB Bioteknologi — DNB · 2.37 % (full portfolio disclosed, September 2026)
- DNB Health Care — DNB · 1.22 % (full portfolio disclosed, September 2026)
- BNP Health Care Innovators — BNP Paribas · 1.15 % (full portfolio disclosed, June 2026)
- BNP US Small Cap — BNP Paribas · 1.13 % (full portfolio disclosed, June 2026)
- JPM US Small Cap Growth Fund — JPM · 1.1 % (full portfolio disclosed, June 2026)
- BNP US Growth — BNP Paribas · 0.97 % (full portfolio disclosed, June 2026)
- Franklin Biotechnology Discovery Fund — Franklin Templeton · 0.41 % (full portfolio disclosed, September 2026)
Showing the 8 largest of 15 funds holding it.